Open Label Randomized Phase II Trial of Nivolumab + Cabiralizumab (BMS-986227, FPA008) + Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabiralizumab (Primary) ; Gemcitabine (Primary) ; Nivolumab (Primary)
Indications Adenocarcinoma; Pancreatic cancer
Focus Therapeutic Use
Acronyms GemCaN Trial

Most Recent Events

06 Feb 2025 Status changed from suspended to completed.
27 Apr 2023 Planned End Date changed from 1 Dec 2021 to 1 Dec 2023.
27 Apr 2023 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight